2002
Signal Transduction Abnormalities as Therapeutic Targets
Halaban R, von Willebrand M. Signal Transduction Abnormalities as Therapeutic Targets. Current Clinical Oncology 2002, 287-323. DOI: 10.1007/978-1-59259-159-6_11.Peer-Reviewed Original ResearchGrowth factor-mediated signalingNormal melanocytesChronic myelogenous leukemiaSignal transduction targetsSpecific kinase inhibitorsCell cycle regulatorsCell cycle progressionAutonomous cell proliferationEpidermal growth factor receptor familyEffective tumor suppressorSignal transduction abnormalitiesGrowth factor receptor familyMelanoma cellsTyrosine kinase receptorsFactor receptor familyReceptor kinaseEnvironmental cuesRegulatory proteinsActive Abl kinasesCycle regulatorsCycle progressionTumor suppressorAbl kinaseKinase receptorsOncogenic mutations
1992
Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.
Halaban R, Rubin J, Funasaka Y, Cobb M, Boulton T, Faletto D, Rosen E, Chan A, Yoko K, White W. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 1992, 7: 2195-206. PMID: 1331934.Peer-Reviewed Original ResearchConceptsHGF/SFMast cell growth factorSignal transductionBasic fibroblast growth factorProtein kinase/extracellular signal-regulated kinaseHuman melanocytesMalignant human melanocytesExtracellular signal-regulated kinaseHepatocyte growth factor/scatter factorGrowth factor/scatter factorSignal-regulated kinaseActivation of microtubuleProto-oncogene c-metTransmembrane tyrosine kinase receptorActivation of METC-MetTyrosine kinase receptorsNormal human melanocytesGrowth factorMouse melanocytesTyrosine phosphorylationBiological roleFibroblast growth factorKinase receptorsConstitutive activity